- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05471726
Améliorer l'utilisation des antimicrobiens après le congé
Améliorer l'utilisation des antimicrobiens après la sortie : une étude d'essai multicentrique en plusieurs étapes
One in five hospitalized patients is prescribed an antimicrobial at the time of discharge, and a large proportion of these post-discharge antimicrobials are unnecessary. The investigators will evaluate a novel method for reviewing post-discharge antimicrobial prescriptions in real-time with the goal of improving antimicrobial selection and duration.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Antimicrobial stewardship programs (ASPs) work to improve antibiotic prescribing within hospitals. ASPs often restrict their activities to inpatient antimicrobial-prescribing. However, at least 40% of all antimicrobial exposure associated with an acute-care hospital stay is prescribed at the time of hospital discharge (i.e., post-discharge). Post-discharge antimicrobials mediate clinical outcomes after discharge and may facilitate the spread of antimicrobial resistance.
Several studies have shown that post-discharge antimicrobial use is often inappropriate. For example, using national VA data, the investigators found that 61% of fluoroquinolone treatment days were prescribed at hospital discharge; manual chart reviews at 9 hospitals found that 40% of these post-discharge fluoroquinolone prescriptions were either unnecessary or sub-optimal. Other studies have found that 53-79% of all post-discharge antimicrobials are either unnecessary or sub-optimal.
Post-discharge antimicrobials are an important target for antimicrobial stewardship. However, inpatient stewardship metrics do not capture post-discharge antimicrobials and ASPs frequently do not evaluate these prescriptions. A 2016 VA survey found that less than 50% of hospitals routinely reviewed targeted antimicrobials at discharge. According to a 2016 survey in Michigan, only 17% of 48 hospitals had a process for reviewing outpatient antimicrobial orders at discharge.
It is unclear how inpatient stewardship resources can be effectively leveraged to improve post-discharge antimicrobial use. If the goal is to improve post-discharge antimicrobial use, a potentially effective strategy may be an audit-and-feedback process focused solely on prescriptions for patients who will soon be discharged. In this trial, the investigators will evaluate the feasibility and effectiveness of such a process.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Richard Roudebush VA Medical Center
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201-1524
- Baltimore VA Medical Center
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Barnes Jewish Hospital and affiliated hospitals
-
-
Texas
-
San Antonio, Texas, États-Unis, 78229
- Audie L Murphy VA Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
--The local stewardship team agrees to implement the discharge stewardship intervention on at least one inpatient service or ward.
Exclusion Criteria:
--The hospital already has an audit-and-feedback process in place that focuses on antimicrobial prescribing at hospital discharge.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Prospective audit-and-feedback at discharge
When hospitals are in the intervention arm, they will perform the audit-and-feedback process focused on patients receiving antimicrobials who have an anticipated discharge. |
The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge. |
|
Aucune intervention: Standard of care
When hospitals are in the control arm, they will not perform a stewardship process that focuses on hospital discharge. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Patients With Post-discharge Antibiotic Exposure
Délai: Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
Post-discharge antibiotic exposure captures the number of hospitalized patient who were discharged with an antibiotic to take after discharge. |
Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
|
Length of Post-discharge Antibiotic Therapy
Délai: Antibiotics prescribed at the point of hospital discharge
|
Duration in days of the post-discharge antibiotics that were prescribed |
Antibiotics prescribed at the point of hospital discharge
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Inpatient Antibiotic Length of Therapy
Délai: Every two-week period through study completion (48 weeks total)
|
Inpatient antibiotic LOT will be calculated by measuring inpatient LOT across all patients exposed to inpatient antibiotics on the participating services during the study period. |
Every two-week period through study completion (48 weeks total)
|
|
Percentage of Participants With Hospital Readmission
Délai: 30 days from discharge
|
Hospital readmissions reflect the need for (re) admission to an acute-care bed at a participating facility for any indication within 30 days of the patient's discharge. |
30 days from discharge
|
Collaborateurs et enquêteurs
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB 202109288
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All data will be aggregated to the hospital-level without including patient identifiers. This is a requirement for transmitting data across the institutions participating in this trial.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .